Antiplatelet effect of mirtazapine via co-blocking of the 5-HT2A and α2-adrenergic receptors on platelets

Yohei Kawano, Maho Katsuyama, Masashi Nagata, Maki Obana, Satoshi Nakamatsu, Ayano Mori, Namiki Sakamoto, Yasunari Mano, Kenichi Negishi, Shuji Shimada, Takao Aoyama

研究成果: Article査読

3 被引用数 (Scopus)

抄録

Mirtazapine (MTZ) is a noradrenergic and specific serotonergic antidepressant. MTZ is reportedly associated with an increased risk of bleeding. However, the underlying mechanism remains unclear. In this study, we investigated the antiplatelet effect of MTZ in mice via light transmission aggregometry to elucidate the mechanism of MTZ-induced bleeding. The results of the ex vivo study showed that the oral administration of MTZ (20 or 100mg/kg) significantly suppressed platelet aggregation mediated by the synergic interaction of 5-hydroxytryptamine (5-HT) and adrenaline. Additionally, MTZ significantly suppressed platelet aggregation, mediated by the synergic interaction of ADP and 5-HT or adrenaline. Similar results were obtained in vitro, under the condition of 5-HT- and adrenaline-induced platelet aggregation. Overall, the results suggest that MTZ exerts antiplatelet effect by co-blocking 5-HT2A and α2-adrenergic receptors on platelets and suppresses platelet aggregation mediated by ADP, increased by either 5-HT or adrenaline. Thus, a detailed monitoring of bleeding is recommended for patients taking MTZ.

本文言語English
ページ(範囲)238-244
ページ数7
ジャーナルBiological and Pharmaceutical Bulletin
44
2
DOI
出版ステータスPublished - 1 2月 2021

フィンガープリント

「Antiplatelet effect of mirtazapine via co-blocking of the 5-HT2A and α2-adrenergic receptors on platelets」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル